Skip to main
TEM

TEM Stock Forecast & Price Target

TEM Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 25%
Hold 25%
Sell 8%
Strong Sell 0%

Bulls say

Tempus AI Inc. exhibited a robust financial performance, with total revenue increasing by 84.7% year-over-year, supported by a significant 117.2% growth in Genomics revenue, which reached $252.9 million. The company is likely to realize higher average selling prices (ASPs) from its xF liquid biopsy assay and xT CDx test, contributing to improved margins and overall revenue from its oncology testing services. Additionally, Tempus anticipates growth through the potential for new pharmaceutical contracts and upcoming reimbursement for its minimal residual disease (MRD) testing, further strengthening its financial outlook.

Bears say

Tempus AI Inc. is experiencing a concerning decline in gross margins, with a drop from 76.8% in Q3 of the previous year to 69.7% in the current period, raising concerns about the company's profitability. The company faces significant risks, including competition, regulatory challenges, and difficulties in acquiring or retaining partnerships, which may further impede its ability to achieve sustainable profitability amid continued operating losses. Despite reporting revenue of $334.2 million that exceeded expectations, the substantial decrease in operating cash flow and the presence of debt on its balance sheet underscore the financial instability that could negatively impact its future growth prospects.

TEM has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tempus AI Inc (TEM) Forecast

Analysts have given TEM a Buy based on their latest research and market trends.

According to 12 analysts, TEM has a Buy consensus rating as of Apr 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $72.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $72.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tempus AI Inc (TEM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.